Treatment of depression and ptsd

Abstract

Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50-200 IU, preferably 120-170 IU, more preferably 140-160 IU, of hCG per day.

1 - 18 . (canceled) 
     
     
         19 . A method of treating an anxiety disorder in a subject that has experienced a serious injury, comprising administering to the subject hCG at a subcutaneous dosage of 50 IU per day to 200 IU per day or a dosage equivalent to a subcutaneous dosage amount of 50 IU per day to 200 IU per day, wherein the method of treating includes treating at least one symptom of the anxiety disorder. 
     
     
         20 . The method of  claim 19 , wherein the anxiety disorder is a disorder that includes a symptom of avoiding stimuli associated with the serious injury. 
     
     
         21 . The method of  claim 19 , wherein the anxiety disorder is a disorder that includes a symptom of re-experiencing one or more events related to the serious injury. 
     
     
         22 . The method of  claim 19 , wherein the anxiety disorder is post traumatic stress disorder. 
     
     
         23 . The method of  claim 19 , wherein the method comprises activating the central nervous system LH/hCG receptor. 
     
     
         24 . The method of  claim 19 , wherein the hCG is administered as a subcutaneous dosage of between 120 IU per day and 170 IU per day of hCG. 
     
     
         25 . The method of  claim 19 , wherein the hCG is administered as a dosage equivalent to a subcutaneous dosage amount of between 120 IU per day and 170 IU per day of hCG. 
     
     
         26 . The method of  claim 19 , wherein the hCG is administered as a subcutaneous dosage of between 140 IU per day and 160 IU per day of hCG. 
     
     
         27 . The method of  claim 19 , wherein the hCG is administered as a dosage equivalent to a subcutaneous dosage amount of between 140 IU per day and 160 IU per day of hCG. 
     
     
         28 . The method of  claim 19 , wherein the hCG is administered once per day. 
     
     
         29 . The method of  claim 19 , wherein the hCG is administered once daily for at least 1 week. 
     
     
         30 . The method of  claim 19 , wherein the hCG is administered once daily for at least 3 weeks. 
     
     
         31 . The method of  claim 19 , wherein the hCG is administered once daily for at least 6 weeks. 
     
     
         32 . The method of  claim 19 , wherein the hCG is administered chronically. 
     
     
         33 . The method of  claim 19 , wherein the hCG is administered as a subcutaneous dosage that consists essentially of hCG. 
     
     
         34 . A method of activating the central nervous system LH/hCG receptor in a subject, comprising administering to the subject hCG at a subcutaneous dosage of 50 IU per day to 200 IU per day or a dosage equivalent to a subcutaneous dosage amount of 50 IU per day to 200 IU per day. 
     
     
         35 . The method of  claim 34 , wherein the hCG is administered as a subcutaneous dosage of between 120 IU per day and 170 IU per day of hCG. 
     
     
         36 . The method of  claim 34 , wherein the hCG is administered as a dosage equivalent to a subcutaneous dosage amount of between 120 IU per day and 170 IU per day of hCG. 
     
     
         37 . The method of  claim 34 , wherein the hCG is administered as a subcutaneous dosage of between 140 IU per day and 160 IU per day of hCG. 
     
     
         38 . The method of  claim 34 , wherein the hCG is administered as a dosage equivalent to a subcutaneous dosage amount of between 140 IU per day and 160 IU per day of hCG.